HAS2 and cancer: For example, increases in hyaluronidases, HAS and HA receptors are significantly linked to reduced survival in colorectal (e.g., HAS2, HMMR, CD44, HYAL1, p = 0.013) (62), and breast [e.g., HAS2, HMMR, HYAL2, p = 0.023, (63) and p = 5.24e-3(64)] cancers.